Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion–Mutated Breast Cancer

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.23.00174 JCO Precision Oncology no. 7 (2023) e2300174. Published online July 24, 2023. PMID: 37487149 Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion–Mutated Breast Cancer Sean R. O'Neil , MD1xSean R. O'NeilSearch for articles by this author; Garrett A. Weber, MD1,2xGarrett A. WeberSearch for articles by this author; Dustin A. Deming , MD3xDustin A. DemingSearch for articles by this author; Mark E. Burkard , MD3xMark E. BurkardSearch for articles by this author; Paraic A. Kenny , PhD4xParaic A. KennySearch for articles by this author; Craig S. Richmond , PhD4xCraig S. RichmondSearch for articles by this author; and Benjamin M. Parsons , DO2xBenjamin M. ParsonsSearch for articles by this author Show More 1Department of Medical Education, Gundersen Health System, La Crosse, WI2Department of Medical Oncology, Gundersen Health System, La Crosse, WI3Department of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, WI4Kabara Cancer Research Institute, Gundersen Health System, La Crosse, WI https://doi.org/10.1200/PO.23.00174 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by the Gundersen Medical Foundation with support for B.M.P., DO.AUTHOR CONTRIBUTIONSConception and design: Paraic A. Kenny, Benjamin M. ParsonsFinancial support: Benjamin M. ParsonsAdministrative support: Dustin A. Deming, Benjamin M. ParsonsProvision of study materials or patients: Benjamin M. ParsonsCollection and assembly of data: Sean R. O'Neil, Mark E. Burkard, Paraic A. Kenny, Craig S. Richmond, Benjamin M. ParsonsData analysis and interpretation: Sean R. O'Neil, Garrett A. Weber, Dustin A. Deming, Mark E. Burkard, Paraic A. Kenny, Benjamin M. ParsonsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Sean R. O'NeilEmployment: Gundersen Health SystemDustin A. DemingConsulting or Advisory Role: Bayer, Lilly, Pfizer, SeagenResearch Funding: Merck (Inst), Bristol Myers Squibb (Inst), Genentech (Inst), Revolution Medicines (Inst), Millennium (Inst), Bayer (Inst), Lilly (Inst), Arcus Ventures (Inst), Curegenix (Inst), Natera (Inst), Promega (Inst), AADi (Inst), Strata Oncology (Inst)Mark E. BurkardConsulting or Advisory Role: Strata Oncology, Novartis, LifeOmicResearch Funding: AbbVie (Inst), Strata Oncology (Inst), Puma Biotechnology (Inst), Loxo (Inst), Merck (Inst), Arcus Ventures (Inst), Apollomics (Inst), Elevation Oncology (Inst), Genentech (Inst), Seagen (Inst), Endeavor BioMedicines (Inst)Patents, Royalties, Other Intellectual Property: I have patent for implantable/localized drug delivery devices that can sample the tumor microenvironment and deliver drug, I have a patent for a method to detect recombination events with CRISPR-mediated editing, and I have a patent for conducting expansion microscopy without specialized equipmentTravel, Accommodations, Expenses: LifeOmicParaic A. KennyPatents, Royalties, Other Intellectual Property: Patent application on antibody-drug conjugates against cleaved amphiregulin (US 17/836,517)Other Relationship: Tegus, Guidepoint GlobalCraig S. RichmondEmployment: Gundersen Health SystemResearch Funding: Gundersen Medical FoundationTravel, Accommodations, Expenses: Gundersen Medical FoundationBenjamin M. ParsonsConsulting or Advisory Role: Celgene, Amgen, AstraZenecaSpeakers' Bureau: Amgen, Celgene, AstraZenecaOpen Payments Link: https://openpaymentsdata.cms.gov/physician/795031No other potential conflicts of interest were reported.